Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Evoke Pharma (EVOK)

Evoke Pharma (EVOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Evoke Pharma Reports Second Quarter 2022 Financial Results Globe Newswire - Wed Aug 10, 2022

Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%...

EVOK : 0.4788 (-12.79%)
Evoke Pharma to Report Second Quarter Results on August 10, 2022 Globe Newswire - Wed Aug 3, 2022

SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 0.4788 (-12.79%)
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD) Globe Newswire - Mon Aug 1, 2022

Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7...

EVOK : 0.4788 (-12.79%)
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program Globe Newswire - Wed Jun 15, 2022

SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...

EVOK : 0.4788 (-12.79%)
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update Globe Newswire - Wed Jun 8, 2022

SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...

EVOK : 0.4788 (-12.79%)
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported Globe Newswire - Mon May 23, 2022

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients...

EVOK : 0.4788 (-12.79%)
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022 Globe Newswire - Tue May 3, 2022

SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 0.4788 (-12.79%)
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results Globe Newswire - Tue Mar 8, 2022

Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales,...

EVOK : 0.4788 (-12.79%)
Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 Globe Newswire - Tue Mar 1, 2022

SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 0.4788 (-12.79%)
Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022 Globe Newswire - Thu Feb 24, 2022

Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study...

EVOK : 0.4788 (-12.79%)

Barchart Exclusives

3 Energy Dividend Stocks Leading the S&P 500 Higher Barchart - Thu Apr 18, 6:30PM CDT
These three energy dividend stocks have outperformed the S&P 500 on a year-to-date basis, and rank among the index's top 20 performers of 2024 so far. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot